Endocyte Announces Closing of Public Offering of Common Stock
March 02, 2018 16:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, March 02, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the...
Endocyte Announces Pricing of Public Offering of Common Stock
February 28, 2018 09:18 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,...
Endocyte Announces Proposed Public Offering of Common Stock
February 27, 2018 18:49 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today...
Endocyte Appoints Patrick Machado, J.D. to Its Board of Directors
February 27, 2018 16:01 ET
|
Endocyte, Inc.
– Patrick Machado, Co-founder and Former Chief Business and Financial Officer of Medivation, Brings Significant Experience in Building Value in the Prostate Cancer Space – WEST LAFAYETTE, Ind., Feb. ...
Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial
February 26, 2018 08:00 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind. and MUNICH, Germany, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), and ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company,...
Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results
February 26, 2018 08:00 ET
|
Endocyte, Inc.
– Phase 3 VISION Trial Design Finalized for 177Lu-PSMA-617 Following Successful End of Phase 2 Meeting with the FDA – – Announced Agreement for Clinical Supply of No-Carrier-Added...
Endocyte Announces Fourth Quarter and Full Year 2017 Earnings Conference Call
February 22, 2018 16:01 ET
|
Endocyte, Inc.
West Lafayette, Ind., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Feb. 26th, at 8:30 a.m. EST to discuss...
Endocyte Added to NASDAQ Biotechnology Index
December 15, 2017 08:00 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
Endocyte to Present at the Jefferies 2017 London Healthcare Conference
November 09, 2017 16:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
Endocyte Reports Third Quarter Financial Results
November 06, 2017 16:01 ET
|
Endocyte, Inc.
– Plans to Initiate Phase 3 Registration for 177Lu-PSMA-617 Accelerated by Radiomedix Agreement to Transfer Active U.S. Investigational New Drug Application (IND) to Endocyte – – The...